N-terminal modifications leading to peptide ORL1 partial agonists and antagonists

被引:14
|
作者
Judd, AK
Kaushanskaya, A
Tuttle, DJ
Sanchez, A
Khroyan, T
Polgar, W
Toll, L
机构
[1] SynVax Inc, N Logan, UT 84341 USA
[2] Stanford Univ, Med Ctr, Beckman Ctr, Prot & Nucleic Acid Facil, Palo Alto, CA 94304 USA
[3] SRI Int, Menlo Pk, CA 94025 USA
来源
JOURNAL OF PEPTIDE RESEARCH | 2003年 / 62卷 / 05期
关键词
affinity; agonists; antagonists; nociceptin; orphanin; peptides;
D O I
10.1034/j.1399-3011.2003.00077.x
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Nociceptin/Orphanin FQ (N/OFQ) is a 17 amino acid peptide that is the endogenous ligand for the G protein-coupled receptor (opioid receptor like 1, ORL1), a member of the opioid receptor family. Although it is clear that this receptor system is involved in a variety of physiological functions, including analgesia, the precise actions of N/OFQ remain largely uncharacterized. One reason for this has been limited high affinity ligands to ORL1, and particularly the lack of availability of useful specific antagonists. Herein we describe the pharmacological activity of a series of N-terminally modified hexapeptides with high affinity for ORL1. These compounds were tested for binding affinity using [H-3]N/OFQ binding to human ORL1 in CHO cells, and functional activity by measuring stimulation of [S-35]GTPgammaS binding in CHO cell membranes. The N-terminal modifications have produced compounds that maintained very high receptor affinity, but led to significant changes in intrinsic activity. One compound, pentanoyl-RYYRWR-NH2, with barely measurable agonist activity was tested in vivo. It was found to possess modest analgesic activity, but it was unable to block the morphine modulatory activity of N/OFQ.
引用
收藏
页码:191 / 198
页数:8
相关论文
共 50 条
  • [1] Unexpected Sensitivity of sst2 Antagonists to N-Terminal Radiometal Modifications
    Fani, Melpomeni
    Braun, Friederike
    Waser, Beatrice
    Beetschen, Karin
    Cescato, Renzo
    Erchegyi, Judit
    Rivier, Jean E.
    Weber, Wolfgang A.
    Maecke, Helmut R.
    Reubi, Jean Claude
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53 (09) : 1481 - 1489
  • [2] Discovery of novel arylpyrazole series as potent and selective opioid receptor-like 1 (ORL1) antagonists
    Kobayashi, Kensuke
    Uchiyama, Minaho
    Ito, Hirokatsu
    Takahashi, Hirobumi
    Yoshizumi, Takashi
    Sakoh, Hiroki
    Nagatomi, Yasushi
    Asai, Masanori
    Miyazoe, Hiroshi
    Tsujita, Tomohiro
    Hirayama, Mioko
    Ozaki, Satoshi
    Tani, Takeshi
    Ishii, Yasuyuki
    Ohta, Hisashi
    Okamoto, Osamu
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (13) : 3627 - 3631
  • [3] Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist
    Li, Jinglan
    Isozaki, Kaname
    Okada, Kazushi
    Matsushima, Ayami
    Nose, Takeru
    Costa, Tommaso
    Shimohigashi, Yasuyuki
    BIOORGANIC & MEDICINAL CHEMISTRY, 2008, 16 (05) : 2635 - 2644
  • [4] Recent advances towards the discovery of ORL-1 receptor agonists and antagonists
    Bignan, GC
    Connolly, PJ
    Middleton, SA
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2005, 15 (04) : 357 - 388
  • [5] Lead generation and lead optimisation approaches in the discovery of selective, non-peptide ORL-1 receptor agonists and antagonists
    Ronzoni, S
    Peretto, L
    Giardina, GAM
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2001, 11 (04) : 525 - 546
  • [6] Binding and GTPγS autoradiographic analysis of preproorphanin precursor peptide products at the ORL1 and oploid receptors
    Neal, CR
    Owens, CE
    Taylor, LP
    Hoversten, MT
    Akil, H
    Watson, SJ
    JOURNAL OF CHEMICAL NEUROANATOMY, 2003, 25 (04) : 233 - 247
  • [7] Protein amino-terminal modifications and proteomic approaches for N-terminal profiling
    Lai, Zon W.
    Petrera, Agnese
    Schilling, Oliver
    CURRENT OPINION IN CHEMICAL BIOLOGY, 2015, 24 : 71 - 79
  • [8] Oxidative stress-mediated N-terminal protein modifications and MS-based approaches for N-terminal proteomics
    Lee, Seon Hwa
    Oe, Tomoyuki
    DRUG METABOLISM AND PHARMACOKINETICS, 2016, 31 (01) : 27 - 34
  • [9] Optimization of benzimidazole series as opioid receptor-like 1 (ORL1) antagonists: SAR study directed toward improvement of selectivity over hERG activity
    Kobayashi, Kensuke
    Kato, Tetsuya
    Yamamoto, Izumi
    Shimizu, Atsushi
    Mizutani, Sayaka
    Asai, Masanori
    Kawamoto, Hiroshi
    Ito, Satoru
    Yoshizumi, Takashi
    Hirayama, Mioko
    Ozaki, Satoshi
    Ohta, Hisashi
    Okamoto, Osamu
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (11) : 3100 - 3103
  • [10] Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: Research tools and potential therapeutic agents
    Zaveri, N
    LIFE SCIENCES, 2003, 73 (06) : 663 - 678